FcγRIIa Antibody Assays for Reproducible Platelet Reactivity Testing

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current assays for platelet reactivity are sensitive to external factors and lack reproducibility, failing to accurately identify individuals at risk of thrombosis and guide appropriate therapeutic regimens.

Innovation Solution

Development of monoclonal antibodies that bind to FcγRIIa, allowing for assays to quantify platelet reactivity by flow cytometry, independent of anticoagulants and patient treatment, with methods to determine FcγRIIa levels on platelets and compare them to reference values to identify increased risk of thrombosis or need for anti-thrombotic therapy.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current assays for platelet reactivity are used, then platelet reactivity can be measured, but the results are sensitive to external factors and lack reproducibility

Engineering Contradiction:

Improvereproducibility of platelet reactivity assayVSAvoidsensitivity to external factors and medications

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent extracts and measures a specific molecular marker (FcγRIIa) on platelet surface that is independent of medication effects. By focusing on this isolated biomarker rather than overall platelet function, the assay achieves reproducibility without being sensitive to external factors like anticoagulants or antiplatelet medications.

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent introduces FcγRIIa as an intermediary biomarker that mediates between platelet reactivity and measurable outcomes. This intermediary marker provides a stable, quantifiable measure that reflects platelet activation state without being directly influenced by medications, thereby resolving the contradiction between reliability and sensitivity to external factors.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Measurement precision

If current platelet reactivity assays are used, then platelet function can be assessed, but they fail to accurately identify individuals at risk of thrombosis

Engineering Contradiction:

Improveaccuracy of thrombosis risk identificationVSAvoidconsistency of assay results

Core Design Contradiction:

Measurement precisionVSReliability

Solution Approach 1:

The patent replaces functional platelet aggregation assays with a molecular detection approach using flow cytometry to measure FcγRIIa expression. This substitution transitions from measuring complex platelet mechanics (aggregation) to detecting a specific molecular marker, achieving both higher precision in risk identification and greater reliability through standardized measurement.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

3Adaptability or versatility

If conventional platelet reactivity testing is performed, then therapeutic regimen selection can be guided, but the tests are influenced by patient treatment and anticoagulants

Engineering Contradiction:

Improveutility in guiding anti-thrombotic therapyVSAvoidinfluence of anticoagulants and patient treatment

Core Design Contradiction:

Adaptability or versatilityVSObject-affected harmful factors

Solution Approach 1:

The patent performs preliminary measurement of FcγRIIa expression on platelets before treatment effects can alter platelet function. Since FcγRIIa is constitutively expressed on platelet surface, this baseline measurement provides treatment-independent information that can guide anti-thrombotic therapy selection without being confounded by ongoing medication effects.

Inventive Principle:

Principle #10Preliminary action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Provides a reliable and reproducible method to assess platelet reactivity, enabling accurate identification of individuals at risk of thrombosis and guiding personalized anti-thrombotic therapy.

Implementation Method 1

monoclonal antibodies able to recognize and bind to FcγRIIa

Methodology Applied

Scientific EffectAntibody-antigen binding:

Implementation Method 2

The sample may be analyzed with the use of flow cytometry

Methodology Applied

Scientific EffectFlow cytometry:

Implementation Method 3

Platelets in the sample are then fixed by adding a suitable fixative

Methodology Applied

Scientific EffectFixation:

Data Source

PatentUS20260055190A1ANTIBODIES FOR PLATELET FCyRIIA AND RELATED METHODS OF USE

Publication Date: 2026.02.26 UNIVERSITY OF VERMONT

AI summary

Antibodies that interact with FcγRIIa are described. Methods of detecting the amount of FcγRIIa on platelets in a sample using antibodies to FcγRIIa are described. Methods of treating a selected subject at risk of thrombosis with an anti-thrombotic therapy are described involving administering aspirin, cilostazol or an anti-thrombotic agent that is an Adenosine diphosphate (ADP) receptor antagonist and/or a Protease-activated receptor (PAR) antagonist to the selected subject, wherein the subject is selected by determining a level of FcγRIIa expressed on platelets by detecting the amount of FcγRIIa in a sample using antibodies to FcγRIIa. In certain methods, elevated levels of FcγRIIa expression identify the subject as at risk of thrombosis and in need for anti-thrombotic therapy.